๐Ÿ”ฌDeep Research

ADCT โ€” Adc Therapeutics SA ยท catalysts, narrative & risks

ยท17 sourcesADCT forecast โ†’

Company Snapshot

ADC Therapeutics SA is a commercial-stage antibody drug conjugate (ADC) company headquartered in Lausanne, Switzerland, with operations in New Jersey, focused primarily on ZYNLONTA (loncastuximab tesirine-lpyl) for diffuse large B-cell lymphoma (DLBCL). [1] [9] It trades on the NYSE under ticker ADCT. [9] As of the October 2, 2026 close, the stock traded near ~$1.13 with a market capitalization of approximately $144 million. [8] [12] [16]


AI-assisted research from the K3vl4r desk โ€” not personalized investment advice. More research โ†’